JNJ 9968
Alternative Names: JNJ-9968Latest Information Update: 23 Feb 2024
At a glance
- Originator Johnson & Johnson Innovative Medicine
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies